Cabometyx
FDA Approves Cabometyx for pNET and epNET
The FDA granted approval for cabozantinib (Cabometyx, Exelixis) for adult and pediatric patients 12 years of age ...
MARCH 26, 2025
Cabozantinib Beneficial in Radioactive Iodine-Refractory DTC
Cabozantinib significantly improved progression-free survival in certain patients with radioactive ...
NOVEMBER 3, 2021
Cabometyx Approved for Metastatic Differentiated Thyroid Cancer
The FDA approved cabozantinib (Cabometyx, Exelixis) for adult and pediatric patients 12 years of age and older with ...
SEPTEMBER 30, 2021
Nivolumab With Cabozantinib Yields Benefits in First-Line Advanced RCC Treatment
The combination of nivolumab plus cabozantinib has clinically meaningful and sustained efficacy and quality-of-life ...
MAY 14, 2021
Load more